Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues
- First Online:
- 52 Downloads
Acute infection with the hepatitis B virus resolves in 95% of adults with no need for specific medical therapy. However, a few cases present as severe hepatitis or acute liver failure, which may require orthotopic liver transplantation or cause death. Under these circumstances, medical therapy that can improve the clinical outcome and improve spontaneous survival would be highly useful; yet, published data regarding the utility of antiviral therapy in acute hepatitis B is quite limited. In this paper, the efficacy and safety of oral nucleoside and nucleotide analogues in the treatment of acute hepatitis B are reviewed, and guidelines for treatment of these acute cases are revisited.
KeywordsAcute hepatitis Nucleotide analogue Nucleoside analogue Lamivudine Entecavir Telbivudine Adefovir Tenofovir Therapy Fulminant hepatic failure
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 30.• Kumar M, Satapathy S, Monga R, et al.: A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007, 45:97–101. This article describes the largest prospective study that evaluated lamivudine therapy in acute hepatitis B, with other larger studies being references 28 and 29.CrossRefPubMedGoogle Scholar
- 33.• Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001–2006. This article is a report of severe lactic acidosis in a case series of patients with hepatitis B cirrhosis and significantly impaired liver function while on entecavir therapy.CrossRefPubMedGoogle Scholar